Takeda (NYSE: TAK ) is currently a unique biopharma case that may lead to opportunities for investors. While the company is facing significant valuation issues, particularly after the costly Shire acquisition, the company has performed deft kaizen to improve their pipeline. In fact, Takeda hasHello, I am an individual investor with an interest in bringing diversification of viewpoints to stock analysis and investing. This brings to point the Japanese proverb 他山之石 -ta-zan-no-ishi- which translates to "anothe ...